Giovanni Bernardini1,2, Giorgia Benigni3, Rossana Scrivo4, Guido Valesini5, Angela Santoni6,7. 1. Dipartimento di Medicina Molecolare, Sapienza Universita' di Roma, 00161, Rome, Italy. 2. IRCCS Neuromed, 86077, Pozzilli, IS, Italy. 3. Innate Immunity Unit, Institut Pasteur, Paris, 75015, France. 4. Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Roma, Italy. 5. Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, Viale del Policlinico 155, 00161, Roma, Italy. guido.valesini@uniroma1.it. 6. Dipartimento di Medicina Molecolare, Sapienza University of Rome, Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Sapienza Universita' di Roma, Viale Regina Elena 291, 00161, Roma, Italy. angela.santoni@uniroma1.it. 7. IRCCS Neuromed, 86077, Pozzilli, IS, Italy. angela.santoni@uniroma1.it.
Abstract
PURPOSE OF REVIEW: The involvement of chemokines and their receptors in the genesis and perpetuation of rheumatoid arthritis, spondyloarthritis, and osteoarthritis has been clearly recognized for a long time. Nevertheless, the complexity of their contribution to these diseases is now becoming evident and this review focuses on published evidence on their mechanism of action. RECENT FINDINGS: Studies performed on patients and in vivo models have identified a number of chemokine-mediated pathways involved in various aspects of arthritogenic processes. Chemokines promote leukocyte infiltration and activation, angiogenesis, osteoclast differentiation, and synoviocyte proliferation and activation and participate to the generation of pain by regulating the release of neurotransmitters. A number of chemokines are expressed in a timely controlled fashion in the joint during arthropathies, regulating all the aspects of inflammation as well as the equilibrium between damage and repair and between relief and pain. Thus, the targeting of specific chemokine/chemokine receptor interactions is considered a promising tool for therapeutic intervention.
PURPOSE OF REVIEW: The involvement of chemokines and their receptors in the genesis and perpetuation of rheumatoid arthritis, spondyloarthritis, and osteoarthritis has been clearly recognized for a long time. Nevertheless, the complexity of their contribution to these diseases is now becoming evident and this review focuses on published evidence on their mechanism of action. RECENT FINDINGS: Studies performed on patients and in vivo models have identified a number of chemokine-mediated pathways involved in various aspects of arthritogenic processes. Chemokines promote leukocyte infiltration and activation, angiogenesis, osteoclast differentiation, and synoviocyte proliferation and activation and participate to the generation of pain by regulating the release of neurotransmitters. A number of chemokines are expressed in a timely controlled fashion in the joint during arthropathies, regulating all the aspects of inflammation as well as the equilibrium between damage and repair and between relief and pain. Thus, the targeting of specific chemokine/chemokine receptor interactions is considered a promising tool for therapeutic intervention.
Authors: Francesco Ciccia; Giuliana Guggino; Aroldo Rizzo; Antonio Manzo; Barbara Vitolo; Marco Pio La Manna; Giuseppina Giardina; Guido Sireci; Francesco Dieli; Carlo Maurizio Montecucco; Riccardo Alessandro; Giovanni Triolo Journal: Rheumatology (Oxford) Date: 2015-07-15 Impact factor: 7.580
Authors: Amelia A Staniland; Anna K Clark; Rachel Wodarski; Oscar Sasso; Francesco Maione; Fulvio D'Acquisto; Marzia Malcangio Journal: J Neurochem Date: 2010-05-28 Impact factor: 5.372
Authors: Daniëlle M Gerlag; Sally Hollis; Mark Layton; Jiří Vencovský; Zoltán Szekanecz; Martin Braddock; Paul P Tak Journal: Arthritis Rheum Date: 2010-11
Authors: Dominique Baeten; Elli Kruithof; Leen De Rycke; Anemieke M Boots; Herman Mielants; Eric M Veys; Filip De Keyser Journal: Arthritis Res Ther Date: 2005-01-21 Impact factor: 5.156
Authors: A L Hansen; L S J Rahbek; A S Sørensen; M P Hundahl; S Lomholt; C K Holm; Tue W Kragstrup Journal: BMC Immunol Date: 2021-12-17 Impact factor: 3.615